<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862926</url>
  </required_header>
  <id_info>
    <org_study_id>RBHIPF004</org_study_id>
    <secondary_id>2012-003633-42</secondary_id>
    <nct_id>NCT01862926</nct_id>
  </id_info>
  <brief_title>Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD</brief_title>
  <acronym>RECITAL</acronym>
  <official_title>A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of East Anglia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and&#xD;
      is the leading cause of death in patients with systemic sclerosis, and contributes&#xD;
      significantly to morbidity and mortality in many other connective tissue diseases (CTDs) such&#xD;
      as polymyositis/dermatomyositis and mixed connective tissue disease. When ILD is extensive&#xD;
      and/or progressive, immunosuppressive medication is often required to stabilize lung disease&#xD;
      and alleviate symptoms. Current standard care for CTD associated ILD is extrapolated from&#xD;
      studies performed in individuals with systemic sclerosis and comprises low dose&#xD;
      corticosteroids and intravenous cyclophosphamide followed by oral azathioprine. In some&#xD;
      individuals even this intensive immunosuppression is insufficient to prevent deterioration,&#xD;
      and in a significant minority of affected individuals this results in respiratory failure and&#xD;
      death. Rituximab has recently been reported as an effective 'rescue therapy' for stabilizing&#xD;
      and even improving ILD in this patient group. Based on observations gained from this&#xD;
      experience, the investigators believe that rituximab is a potential important alternative to&#xD;
      current best therapy for this patient group. This study has therefore been initiated to&#xD;
      evaluate the efficacy of rituximab (compared with standard therapy) in patients with&#xD;
      progressive CTD related ILD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in FVC</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Change from baseline in diffusing capacity for carbon monoxide (DLco)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change from baseline in health related quality of life scores</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change from baseline in global disease activity score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Progression free survival</measure>
    <time_frame>48 weeks</time_frame>
    <description>composite endpoint of mortality, transplant, treatment failure or decline in FVC &gt; 10% compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Adverse and serious adverse events (as defined in GCP)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Scleroderma</condition>
  <condition>Idiopathic Inflammatory Myositis</condition>
  <condition>Mixed Connective Tissue Disease</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g given at baseline and two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80 years at visit 1&#xD;
&#xD;
          -  A diagnosis of connective tissue disease, based on internationally accepted criteria,&#xD;
             in one of the following categories21-24: (see Appendix 1 for details)&#xD;
&#xD;
               -  Systemic sclerosis&#xD;
&#xD;
               -  Idiopathic interstitial myopathy (including polymyositis/dermatomyositis)&#xD;
&#xD;
               -  Mixed connective tissue disease&#xD;
&#xD;
          -  Severe and/or progressive interstitial lung disease associated with the underlying&#xD;
             connective tissue disease.&#xD;
&#xD;
          -  Chest HRCT performed within 12 months of study visit 1&#xD;
&#xD;
          -  Intention of the caring physician to treat the ILD with intravenous cyclophosphamide&#xD;
             (with treatment indications including deteriorating symptoms attributable to ILD,&#xD;
             deteriorating lung function tests, worsening gas exchange or extent of ILD at first&#xD;
             presentation) and where there is a reasonable expectation that immunosuppressive&#xD;
             treatment with stabilize or improve CTD-ILD. In individuals with scleroderma it is&#xD;
             anticipated that subjects will fulfil the criteria for extensive disease defined by&#xD;
             Goh et al19&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 or &gt;80 years.&#xD;
&#xD;
          -  Previous treatment with rituximab and/or intravenous cyclophosphamide&#xD;
&#xD;
          -  Known hypersensitivity to rituximab or cyclophosphamide or their components&#xD;
&#xD;
          -  Significant (in the opinion of the investigator) other organ co-morbidity including&#xD;
             cardiac, hepatic or renal impairment&#xD;
&#xD;
          -  Co-existent obstructive pulmonary disease (e.g. asthma, COPD, emphysema) with pre&#xD;
             bronchodilator FEV1/FVC &lt; 70%&#xD;
&#xD;
          -  Patients at significant risk for infectious complications following immunosuppression,&#xD;
             including; HIV positive or other immunodeficiency syndromes (including&#xD;
             hypogammaglobulineamia)&#xD;
&#xD;
          -  Suspected or proven untreated tuberculosis&#xD;
&#xD;
          -  Viral hepatitis&#xD;
&#xD;
          -  Infection requiring antibiotic treatment in the preceding four weeks&#xD;
&#xD;
          -  Unexplained neurological symptoms (which may be suggestive of progressive mutifocal&#xD;
             leukoencephalopathy; PML). Neurological symptoms arising as a consequence of the&#xD;
             underlying CTD do not necessitate exclusion.&#xD;
&#xD;
          -  Other investigational therapy (participation in research trial) received within 8&#xD;
             weeks of visit 1&#xD;
&#xD;
          -  Immunosuppressive therapy (other than corticosteroids) received within 2 weeks of&#xD;
             visit 1 (randomization)&#xD;
&#xD;
          -  Pregnant or breast feeding women, or women of child-bearing potential, not using a&#xD;
             reliable contraceptive method&#xD;
&#xD;
          -  Unexplained haematuria, or previous bladder carcinoma&#xD;
&#xD;
          -  Unable to provide informed written consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toby M Maher, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Brompton and Harefield Foundation NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumánovics G, Coleiro B, Feierl E, Szucs G, Von Mühlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kötter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi: 10.1136/ard.2009.114264. Epub 2010 Jun 15.</citation>
    <PMID>20551155</PMID>
  </reference>
  <reference>
    <citation>Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006 Dec;54(12):3962-70.</citation>
    <PMID>17133610</PMID>
  </reference>
  <reference>
    <citation>Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012 Sep;40(3):641-8. doi: 10.1183/09031936.00163911. Epub 2012 Jan 26.</citation>
    <PMID>22282550</PMID>
  </reference>
  <reference>
    <citation>Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54. doi: 10.1164/rccm.200706-877OC. Epub 2008 Mar 27.</citation>
    <PMID>18369202</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>connective tissue disease</keyword>
  <keyword>interstitial lung disease</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <keyword>rituximab</keyword>
  <keyword>scleroderma</keyword>
  <keyword>polymyositis</keyword>
  <keyword>dermatomyositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Mixed Connective Tissue Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

